Enter multiple symbols separated by commas

Sales of Anemia Drugs May Be Hurt by New Recommendations

The National Kidney Foundation said Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.

The changes could hurt sales of Amgen key anemia drugs Aranesp and Epogen, which brought in $6.6 billion in 2006, and Johnson & Johnson's

Procrit, which saw $3.2 billion in sales, although some analysts say that drug has become a less-critical product for the company.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video